Title
Immunoglobulin A and liver diseases.

Permalink
https://escholarship.org/uc/item/0ht1n7f0

Journal
Journal of gastroenterology, 53(6)

ISSN
0944-1174

Authors
Inamine, Tatsuo
Schnabl, Bernd

Publication Date
2018-06-01

DOI
10.1007/s00535-017-1400-8

Peer reviewed
Immunoglobulin A and liver diseases

Tatsuo Inamine 1 · Bernd Schnabl 2,3

Abstract Immunoglobulin A (IgA) is a major immunoglobulin isotype in the gut and plays a role in maintenance of gut homeostasis. Secretory IgA (SIgA) has multiple functions in the gut, such as to regulate microbiota composition, to protect intestinal epithelium from pathogenic microorganisms, and to help for immune-system development. The liver is the front-line organ that receives gut-derived products through the portal vein, implying that the liver could be severely affected by a disrupted intestinal homeostasis. Indeed, some liver diseases like alcoholic liver disease are associated with an altered composition of gut microbiota and increased blood endotoxin levels. Therefore, deficiency of SIgA function appears as a significant factor for the pathogenesis of liver diseases associated with altered gut microbiome. In this review, we describe SIgA functions on the gut microbiome and discuss the role of IgA for liver diseases, especially alcoholic liver disease and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis.

Keywords IgA · ALD · NAFLD · NASH · Gut microbiome

Introduction

The human gut microbiota, comprised of 100 trillion bacteria with a high diversity, has established a mutualistic relationship with their host. While hosts provide a nutrient-rich environment, bacteria metabolize indigested foods, produce beneficial products like vitamins, and educate our immune system. Although the gut microbiota homeostasis is tightly regulated by both host and microbiota themselves, deviation from this highly balanced condition influences our health. A disrupted intestinal homeostasis is not only associated with gut disorders like inflammatory bowel diseases [1, 2] but also with extraintestinal manifestations such as obesity [3, 4], diabetes [5, 6], autism spectrum disorder [7, 8], and liver diseases [9–11].

To maintain the homeostasis, the gut mucosa releases anti-microbial peptides and secretory immunoglobulins [12]. Immunoglobulin A (IgA) is a major immunoglobulin isotype in the gut and several grams of IgA are secreted into the intestine each day in humans [13]. Plasma cells in the intestinal lamina propria secrete IgA, which is transcytosed across intestinal epithelial cells by a cellular receptor, polymeric-immunoglobulin receptor (pIgR) [14]. In the gut lumen, secretory IgA controls microbiota composition and also serves as the first-line barrier that binds bacteria, limits contact between bacteria and enterocytes to prevent bacterial invasion [14–16]. Mice that lack functional IgA in the gut showed altered microbial composition and increased susceptibility to infectious diseases [14, 17, 18]. In addition, mice carrying a genetic mutation...
| Human disease/animal model | Subjects | IgA (tissue) | IgA level | References |
|---------------------------|----------|--------------|-----------|------------|
| Human, alcoholics         |          |              |           |            |
| Alcoholic cirrhosis       | Severe cirrhosis with jaundice, compensated cirrhosis, and control | Monomeric IgA and SLgA (perfusion fluid of proximal small intestine) | Severe cirrhosis < compensated cirrhosis = control | [86] |
| Alcoholics                | Alcoholics with cirrhosis, alcoholics without cirrhosis, and control | SLgA (perfusion fluid of jejunum) | Alcoholics with/without cirrhosis = control | [87] |
| Alcoholics                | Alcoholics with recent drink, alcoholics without recent drink, and control | Number of IgA plasma cells (duodenum) | Alcoholics = control | [88] |
| Animal, ALD              |          |              |           |            |
| Wister rat, female       | Intraperitoneal injection of ethanol (4 g/kg) for 30 min | IgA-positive cells (Peyer’s patch and lamina propria of small intestine) | EtOH > saline in lamina propria, EtOH = control in Peyer’s patch | [85] |
| Wister rat, female       | Intraperitoneal injection of ethanol (4 g/kg) for 30 min, ± treatment with NOS inhibitor | IgA-positive cells (ileal lamina propria) | EtOH > EtOH + inhibitor = saline | [84] |
| Wister rat, male         | Intraperitoneal injection of ethanol (4 g/kg) for 30 min, ± treatment with neuronal NOS inhibitor | SLgA (ileal extract) | EtOH > EtOH + inhibitor = saline | [83] |
| Wister rat, male         | Lieber-DeCarli liquid diet for 4 weeks | IgA-positive cells (jejunal and colonic mucosa) | EtOH < control | [81] |
| C57BL/6 mouse, female    | Lieber-DeCarli liquid diet for 8 weeks | SLgA (feces) | EtOH < control | [77] |
| C57BL/6-Ly5.1 mouse      | Lieber-DeCarli liquid diet for 10 days + binge (5 g/kg) for 9 h | IgA-positive plasma cells (small intestinal lamina propria) | EtOH < control | [30] |
| C57BL/6 mouse            | 20% w/v ethanol in drinking water for 10-12 weeks | SLgA (contents of small and large intestine) | EtOH < control | [82] |
| Animal, NAFLD/NASH       |          |              |           |            |
| Sprague–Dawley rat, female | High-fat diet (88% normal + 10% lard + 2% cholesterol) for 8-12 weeks | SLgA (small intestinal mucosa) | HF = < control in 8 weeks, HF < control at 12 weeks | [95] |
| Sprague–Dawley rat, male | High-fat diet (30% w/w beef tallow) for 3 weeks, ± supplied with curcumin | SLgA (feces) | HF + curcumin > HF > LF + curcumin = LF | [92] |
| Sprague–Dawley rat, male | High-fat diet (30% w/w beef tallow) for 3 weeks, ± supplied with sericin | SLgA (feces and colon) | HF + sericin > HF = LF = LF + sericin in feces | [93] |
| Sprague–Dawley rat       | High-fat diet (60% fat energy) for 8 weeks, ± supplied with polyphenols | SLgA (feces) | HF + polyphenols > HF = LF | [96] |
| C57BL/6 mouse, male      | Methionine-choline-deficient diet for 3 weeks, ± supplied with fructo-oligosaccharide | SLgA (feces), IgA-positive cells (ileum and colon) | MCD < control < MCD + fructo-oligosaccharide (SLgA and IgA-positive cells) | [94] |

SLgA secretory IgA, EtOH ethanol, HF high-fat diet, LF low-fat diet, MCD methionine-choline-deficient diet, NOS nitric oxide synthase
in activation-induced cytidine deaminase, which cannot undergo somatic hyper mutation and class switching to IgA and IgG, have bacterial translocation and intestinal bacterial overgrowth [19].

The liver is the front-line organ that receives and responds to gut-derived products through the portal vein, implying that the liver could be severely affected by the disrupted interaction between host and gut microbiota. Indeed, pattern-recognition receptors on Kupffer cells respond to gut-derived bacterial components like lipopolysaccharide (LPS) and contribute to local inflammation [20]. Conversely, the liver also affects gut microbiota through secretion of bile, which contains bile acids and liver-derived IgA, into the intestine. A disrupted homeostasis in the gut has been reported to be associated with chronic liver diseases including primary sclerosing cholangitis, liver cirrhosis, alcoholic liver disease (ALD), and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) [21, 22]. In this review, we will describe the IgA function on the gut microbiome and gut–liver axis, and discuss the potential role of IgA for liver diseases, especially ALD and NAFLD/NASH.

**Source and function of IgA**

In the intestine, naïve B cells are found in the lamina propria immediately underlying the epithelium and are clustered in the gut-associated lymphoid follicles, such as the Peyer’s patches (PP). By presentation of bacterial antigens and aids from T cells in the germinal center of the gut-associated lymphoid follicles, naïve B cells are activated and become IgA-producing plasma cells. In addition, activation of B cells was found to also occur independently from T cells and specific antigens. In general, T cell-dependent IgA production is related to higher specificity and affinity to bacterial antigens than T cell-independent IgA [23]. There are several extensive reviews about this B cell activation and IgA production process in the gut [24, 25].

IgA-producing plasma cells translocate to the lamina propria and work as a main source of the gut IgA. In the lamina propria, plasma cells produce predominantly dimeric IgA and the dimeric IgA is transcytosed across gut epithelium by a membrane receptor, plgR that is expressed on the basolateral surface of epithelial cells. At the apical surface of epithelial cells, the IgA-plgR complex is cleaved and IgA bound to an outer membrane part of plgR, which is known as secretory component (SC), is released as a secretory IgA (SIgA) [14]. Although SIgA produced in the lamina propria constitutes a major part of total IgA in the adult gut, there are two other sources of gut IgA: maternal milk IgA and liver-derived IgA. The milk SIgA is the only source of IgA in the gut of newborn mammals and contributes to the composition of the first gut microbiome [26], instead of endogenous SIgA that starts to be produced several months after birth in humans and slowly increases [27, 28]. On the other hand, liver-derived IgA is produced by plasma cells that colonize portal regions and the submucosa of biliary tracts, and is secreted to bile by plgR on hepatocytes and cholangiocytes [29, 30]. In the human liver, however, plgR is expressed only on cholangiocytes [29]. The proportion of the liver-derived SIgA to total gut SIgA varies between species: low in human and dog, moderate in mouse, and high in rabbit and rat [29]. There is a comprehensive review discussing liver IgA [29].

Although precise mechanisms how SIgA maintains gut homeostasis and protects the host from pathogenic stimuli of bacteria are not known, several mechanisms have been suggested [14, 15]. SIgA prevents the access of bacteria to the apical surface of epithelial cells by agglutinating bacteria and/or entrapping bacteria in the mucus layer. Moreover, binding of immunoglobulins can alter gene expression of some bacteria to reduce their virulence or motility [31, 32]. In addition to direct effects on bacteria, SIgA neutralizes bacterial toxins and protects epithelial cells from the toxic stimulation [14, 15]. Meanwhile SIgA binding inhibits bacterial access and invasion to epithelial cells, SIgA binding to luminal bacteria also promote sampling of the bacteria to PP, leading to induction of a strong response against the bacteria by B and T cells [33]. In general, SIgA exerts these functions without induction of deleterious inflammation at the site [25]. Although precise functions of SIgA that regulate host-microbiota homeostasis in the gut are not well defined, deficiency of SIgA in mice led to altered microbiome in the gut [17, 18] and to increased susceptibility to both pathogens and toxic reagents [17, 34].

**IgA influence on gut microbiome and health**

There are several genetically modified mice which lack or have decreased SIgA in the gut lumen, and these models allow us to investigate the role of SIgA on gut homeostasis and host health. The effects of SIgA deficiency on models of infectious disease have been reviewed [14]. Here, we will focus on IgA influences on gut microbiota composition and gastrointestinal infection of bacteria. Iga<sup>−/−</sup> mice that lack the IgA switch region and the IgA constant region showed altered microbiota shift from newborn to adult [17]. Iga<sup>−/−</sup> mice showed increased and persistent colonization of Enterobacteriaceae family, which is predominant (> 75%) in newborn mice and decreased (< 1%) during the first 6 weeks [17]. It has been reported that the Enterobacteriaceae bacteria family is increased in patients
with Crohn’s disease [2, 35], children with type 1 diabetes [36], and cirrhotic patients [21]. In addition, Iga−/− mice exhibited sustained intestinal inflammation and increased susceptibility to dextran sodium sulfate (DSS)-induced injury [17]. However, Iga−/− mice showed similar susceptibility to oral infection of Citrobacter rodentium infection compared with wild-type mice [37].

There are two other animal models that lack SIgA in the gut: pIgR-deficient and ‘joining’ chain (J chain)-deficient mice. These two mice cannot properly secret IgA or IgM into the gut lumen [14]. Decreased abundance of Bifidobacterium spp., which are known as beneficial bacteria in general, and increased abundance of Helicobacter spp. were observed in the cecum of the Pigr−/− mice [38]. Moreover, the Pigr−/− mice were susceptible to Salmonella typhimurium infection via the fecal–oral route [39] and more vulnerable to DSS-induced colitis than wild-type mice [34, 38]. However, Pigr−/− exhibited similar susceptibility to Citrobacter rodentium [37] and Clostridium difficile as compared with wild-type mice [40]. Immunized J chain-deficient mice were not protected from Cholera toxin [41], while they exhibited similar clearance of Citrobacter rodentium as wild-type mice [37]. There is no clear reason why these mice, lacking gut SIgA, showed normal susceptibility to several bacterial infection models. It is speculated that SIgA effects on simple bacterial infection model could be compensated by other type of immunoglobulins, such as SIgM and IgG, and/or antimicrobial peptides. Indeed, Iga−/− mice exhibited increased SIgM level in the gut [42] and mRNA of antimicrobial peptides were increased in the colon epithelium of Pigr−/− mice [38].

In humans, individuals with selective IgA deficiency have a tendency to develop infections of the gastrointestinal tract (e.g., Giardia infections), celiac disease, and inflammatory bowel diseases [43]. Although selective IgA deficiency showed association with these diseases, 85–90% of IgA-deficient people are asymptomatic. However, there are few reports investigating the characteristics of gut microbiome of human IgA deficiency. Friman’s group demonstrated that IgA-deficient individuals more often had the genes involved in virulence of Escherichia coli in their rectal flora, although only several virulent factors of E. coli were examined [44]. Future studies that investigate IgA-deficiency on the human gut microbiome, will be important for this field of research.

IgA-microbiota on liver diseases

Gut microbiome-liver disease

Dietary factors including alcohol directly and indirectly influence the gut microbiota [45–48]. Intestinal bacterial overgrowth and bacterial dysbiosis after chronic alcohol consumption were observed in animals and human [47]. Intragastric alcohol feeding was associated with bacterial overgrowth in the large intestine as early as 1 week after feeding in mice [49]. Binge drinking of alcohol leads to elevation of blood endotoxin level. Alcohol and its metabolite acetaldehyde disrupts tight junction of epithelial cells and increase intestinal permeability [46]. Mice fed with high-fat diet exhibited altered gut microbiota composition [50, 51] and the change was independent from obesity [51], indicating high-fat diet itself influences gut microbiome composition. In addition, high-fat diet increased intestinal permeability through reduction of tight-junction proteins and induction of intestinal inflammation, leading to elevated blood endotoxin [45].

The mechanisms how altered gut microbiome contributes to development and progression of liver diseases were previously reviewed [20, 21, 47, 48, 52, 53]. Lipopolysaccharide (LPS), known as endotoxin, is a cell-wall component of gram-negative bacteria and interacts with Toll-like receptor 4 (TLR4). As mentioned above, increased level of circulating LPS was observed in patients with ALD and rodent models of ALD [54]. Increased endotoxin is also observed in alcoholic patients with minimal symptoms of ALD [55] and healthy subjects with single binge drinking [56]. In addition, the LPS levels correlate with disease severity [57, 58]. In mice, a LPS increase was observed both by acute binge gavage and chronic feeding with ethanol [59]. In addition to LPS, other bacterial components, such as bacterial 16S DNA and peptidoglycan which is a cell-wall component of gram-positive bacteria, were also increased in the circulating blood [56, 60]. In general, liver-resident macrophages, Kupffer cells, are tolerant to LPS-induced TLR4 activation and eliminate microbial components without inflammatory response. However, prolonged and excessive exposure to LPS can make Kupffer cells sensitive to LPS [20]. Moreover, ethanol-induced hepatocyte damage is associated with the liver macrophage activation through the damage associated molecular pattern production or signaling molecule-containing exosome production [61, 62]. Thus, sensitized Kupffer cells by ethanol-stimulated hepatocytes respond to gut-derived bacterial and fungal components and promote local inflammation in the liver. Other types of microbial products that are derived from the gut, such as bacterial DNA and cell-wall components, are also possible mediators of liver inflammation [20]. Recently, we found 1,3-β-glucan, which is a cell-wall component of fungi, is also increased in alcohol-fed mice and anti-Saccharomyces cerevisiae IgG antibody is significantly higher in alcoholic cirrhosis patients than in healthy individuals or viral cirrhosis patients [63]. Translocating fungi cell-wall component promoted IL-1β processing and local inflammation via its receptor, decitin-1, on liver macrophage cells [63].
Diet-induced endotoxemia is observed in rodent models of obesity and NAFLD/NASH [64–67]. In humans, NAFLD/NASH patients have higher level of systemic endotoxin when compared with healthy people [68, 69]. Infiltration of LPS into the liver has been shown to exacerbate liver injury in NAFLD/NASH mice, possibly via TLR4 activation [70]. Predisposition to obesity, which is a common factor attributed to NAFLD/NASH development, has been shown to be influenced by gut microbiota [71, 72]. Germ-free mice, which do not have any microorganisms in their body, are tolerant to high-fat diet-induced weight gain. By transplantation of gut microbiota from obese mice, but not from lean mice, germ-free mice gained more fat by high-fat diet [73]. That could be mediated by increased energy extraction from diet via altered microbiome. In addition, the production of fasting-induced adipocyte factor (Fiaf) is suppressed by enteric bacteria, resulting in increased activity of lipoprotein lipase and increased accumulation of triglycerides in the liver [21, 71, 72]. High-fat diet altered microbiota composition toward metabolizing dietary choline to methylamines, resulting in reduced level of plasma phosphatidylcholine [21, 74]. Choline-deficient diet, which also reduces phosphatidylcholine, is used to create rodent model of NASH. Reduced level of phosphatidylcholine, which is necessary for assembly of very-low-density lipoprotein (VLDL), results in triglyceride accumulation in the liver [21]. In addition, obese patients and children with NASH showed increased blood ethanol concentration [10, 75]. Increased ethanol produced by altered gut microbiota could possibly be a mediator of liver damage [21, 52].

The role of IgA in NAFLD/NASH and ALD

IgA has been studied in the field of alcoholic liver disease for a long time [76]. Brown and Kloppel reviewed IgA levels in serum and the liver of ALD patients [29]. Systemic IgA levels are increased in patients with alcoholic liver disease [29] and in a rodent model of alcoholic liver disease [77]. In addition, liver IgA deposits appear specific for alcoholic liver disease, correlate with the amount of alcohol consumption, but not with serum IgA concentrations [78–80]. Moro-Sibilot and colleagues demonstrated that mouse and human liver contain IgA-secreting cells. Increased amount of IgA-secreting cells in mice fed with ethanol was diminished by inhibition of IgA-plasmablast egress from Peyer’s Patches with FTY720 that modulates sphingosine-1-phosphate receptor 1 and inhibits the egress of lymphocytes form secondary lymphoid organs, indicating that IgA deposits in the liver of ALD patients is attributed, at least partially, to increased entry of IgA-secreting cells from Peyer’s Patches to the liver [30].

SLgA levels in the gut of chronic liver diseases seems more important than systemic and liver IgA changes because SLgA regulates gut homeostasis. Studies that examined IgA levels in the gut of alcoholic patients and rodent models of ALD and NAFLD/NASH are summarized in Table 1. The number of IgA-secreting plasma cells in the intestinal lamina propria [30] and fecal IgA levels [77], which reflect the amount of colonic IgA, are reduced in experimental models of ethanol-induced liver disease of mice. These decreased SLgA and/or IgA-secreting cells in the intestine are reproducibly observed in rodent models of chronic alcohol feeding [81, 82], but not in rat model of single administration with ethanol [83–85]. Studies investigating intestinal IgA of patients with alcohols are very limited [86–88]. Pelletier et al. observed decreased intestinal secretion of SlgA in patients with severe alcoholic cirrhosis when compared to patients with compensated alcoholic cirrhosis [86]. In contrast, Colombel et al. showed similar levels of jejunal SlgA secretion among alcohols with cirrhosis, alcohols without cirrhosis, and control subjects [87]. Maier and colleagues observed similar number of IgA-secreting cells in duodenum between alcohols and controls, but a slightly decreased IgA amount in IgA-secreting cells of alcohols with recent alcohol intake [88]. These conflicting reports may result from subjects in different stages of the disease or different methods of IgA measurement. Recently, we investigated the role of IgA in a mouse model of ethanol-induced liver disease by using Iga<−/−> mice. Unexpectedly, Iga<−/−> mice fed with ethanol showed similar degrees of liver injury (plasma ALT), hepatic triglyceride accumulation, and liver inflammation as compared with wile-type littermates [77]. Interestingly, we observed increased bacterial translocation to mesenteric lymph node in Iga<−/−> mice fed with control diet, but no further increase of the translocation in Iga<−/−> mice fed with ethanol. The result suggests that exposure of the liver of Iga<−/−> mice to gut-derived bacterial component is increased under physiological conditions and the increased translocation is further regulated by other factors than SlgA during disease. One possible reason why loss of IgA did not affect disease development is a compensation by SlgM. The Iga<−/−> mice fed with ethanol exhibited increased level of fecal IgM [77]. Further studies investigating compensatory roles of intestinal IgM and/or antimicrobial peptides are necessary.

Unlike the case of ALD, reports that investigated an association between serum IgA level and NAFLD/NASH are limited [89–91]. Tomita et al. showed that serum IgA concentration is increased in severe-NASH patients when compared with early-stage NASH patients, although IgA concentrations were comparable among control, simple steatosis, NAFLD, and early-stage NASH [89]. McPherson’s
group showed that serum IgA was elevated in NASH patients as compared with simple steatosis patients [90]. In these studies, serum IgA levels were positively associated with severity of liver fibrosis [89–91]. However, associations between increased serum IgA and advanced stage are also observed in other types of chronic liver diseases. Thus, increased systemic IgA levels in NAFLD/NASH patients may not be a specific marker for the disease progression. Although there is no study that investigated intestinal or fecal IgA levels of NAFLD/NASH patients, several studies using rodent models of NAFLD/NASH showed altered intestinal IgA secretion [92–96]. In the study of Matsumoto’s group, mice with NASH induced by methionine-choline-deficient diet, exhibited decreased fecal IgA and IgA-positive cells in ileal and colonic tissues [94]. In addition, Li et al. showed decreased IgA in small intestinal mucosa of rats fed with high-fat diet, and a negative correlation between the intestinal IgA levels and systemic endotoxin levels [95]. However, similar IgA levels of feces between high-fat and control groups or increased fecal IgA in high-fat group were observed in several studies [92, 93, 96]. Different feeding protocol might explain these results. In the study from Li’s group, decreased SIgA in the small intestine was not observed in 8-week feeding group, but observed in 12-week feeding group [95]. Although the mechanisms how increased systemic IgA and/or reduced intestinal SIgA are involved in disease development and progression are not clear yet, some gut dysbiosis and bacterial overgrowth observed in ALD and NAFLD/NASH might contribute to decreased SIgA levels in the gut.

The role of SIgA on gut microbiome in NAFLD/NASH and ALD

The study of gut SIgA functions in liver diseases is the field that started recently, and SIgA behavior in the gut of human alcoholic patients has not been intensively investigated yet. However, several studies revealed shared features of gut microbiome changes between SIgA-deficient mice and human patients with alcoholic liver disease. As mentioned above, Iga−/− mice exhibited increased colonization of Enterobacteriaceae family (in phylum Proteobacteria) [17]. Increased abundance of phylum Proteobacteria is a signature of intestinal dysbiosis associated with metabolic and inflammatory diseases [97]. Moon et al. found dichotomous fecal IgA levels among wild-type mice in the same facility and the IgA-low phenotype was driven by transmissible fecal bacteria [98]. This IgA-low phenotype of mice was associated with enriched Enterobacteriaceae family. Although increased Enterobacteriaceae family was not observed in IgA-low mice from a different facility in the same study, the phylum Proteobacteria was increased in the mice [98]. These results indicate decreased SIgA may drive the expansion of Enterobacteriaceae family (or phylum Proteobacteria) in the gut of chronic liver diseases, such as ALD and NAFLD/NASH. Increased members of the Enterobacteriaceae family or phylum Proteobacteria is also observed in chronic liver diseases [21]. Zhu et al. and colleagues revealed that abundance of Escherichia spp. (in Enterobacteriaceae family) and Enterobacteriaceae family are increased in stool of children with NASH when compared with healthy children or children with obesity [10]. Increased Gammaproteobacteria class, which includes Enterobacteriaceae family, was also observed in children with NAFLD when compared with healthy children in a different study [99]. A study in which gut microbiota composition were compared between 53 NAFLD patients and 32 healthy subjects showed increased Escherichia spp. in NAFLD patients [100]. Increased abundance of phylum Proteobacteria and/or Enterobacteriaceae family were reproduced in rodent models of NAFLD [101–104]. However, the enrichment of Enterobacteriaceae and Escherichia spp. was not reproduced in human studies [105, 106]. Taken together, decreased amount of SIgA in the gut lumen, which was observed in rats fed with high-fat diet [95], may contribute to expansion of phylum Proteobacteria and/or Enterobacteriaceae family of bacteria and disease pathogenesis.

The prominent feature of dysbiosis observed in alcoholic patients and rodent model of alcoholic liver disease is characterized by a decreased phylum Firmicutes and lower amount of Lactobacillus spp. (in phylum Firmicutes) [49, 107–110]. Probiotic treatment with Lactobacillus spp. and Bifidobacterium spp. improved bacterial dysbiosis and ameliorated liver injury and/or inflammation in both humans and animal models (previously reviewed by Bluemel et al. [111]). In addition to these bacteria, alcoholic patients with dysbiosis showed a higher relative abundance of Gammaproteobacteria class (in phylum Proteobacteria) than alcoholic patients without dysbiosis [112]. Relative abundance of Enterobacteriaceae family was higher in the stool of patients with alcohol hepatitis than alcoholic patients without hepatitis [113]. Increased Enterobacteriaceae is reproducibly observed in human cirrhotic patients [9, 11, 114]. Bajaj et al. proposed the cirrhosis dysbiosis ratio (CDR). The ratio of “good” bacteria, such as Lactobacillus spp., against potentially “bad” bacteria, such as Enterobacteriaceae was lower in advanced cirrhotic patients as compared with that in compensated-cirrhotic patients [58]. Especially, cirrhotic patients with alcoholic etiology showed increased Enterobacteriaceae
family [58]. Although these facts suggest a possible link between reduced SIgA and development of the disease, studies investing direct effects of SIgA on the diseases are limited. Further studies investigating the change of gut microbiome and disease status in SIgA-deficient mice are required.

**Fc receptor alpha I and IgA on liver diseases**

In addition to the SIgA roles in the intestinal lumen, it has been suggested that serum and lamina propria IgA play a role in mucosal immunity via binding to a transmembrane receptor, Fc receptor alpha I (FcαRI) [115]. Functions of FcαRI are previously reviewed [115, 116]. FcαRI is expressed on cells of the myeloid lineage, including neutrophils, eosinophils, and Kupffer cells [116]. In contrast to non-inflammatory functions of SIgA, serum monomeric IgA and dimeric IgA (dIgA) in the lamina propria can induce several pro-inflammatory functions via the binding to FcαRI [115]. Cross-linking of FcαRI by IgA immune complexes (e.g., IgA-coated bacterial cells) mediates the production of reactive oxygen species and lymphokine from neutrophils and promotes phagocytosis by neutrophils and Kupffer cells [115, 117]. However, studies investigating this topic are lacking, because mice do not have an equivalent receptor of the human FcαRI [118].

Egmond’s group revealed serum IgA to eliminate bacteria invading the liver, by using mice with a transgene that is introduced with a cosmid clone containing the human FcαRI gene [117]. Kupffer cells that express the human FcαRI effectively phagocytosed bacteria coated with serum IgA, but not with SIgA. In contrast, the number of phagocytosed bacteria in the liver of non-transgenic mice were only 20% of that of the transgenic mice [117]. In addition, neutrophils from healthy human donors responded to serum IgA and produce leukotriene B4 (LTB4), leading to further recruitment of neutrophils [119]. Mouse neutrophils that express human FcαRI phagocytosed IgA-coated bacteria more than BSA-coated bacteria. In the colon of patients with ulcerative colitis, a number of FcαRI-expressing neutrophils infiltrated the lamina propria and phagocytosed IgA-complexes. In contrast, few neutrophils were observed in the colon of healthy subjects [119]. These results indicate that IgA osonizes bacteria and promotes effective phagocytosis of and elimination of the invading bacteria via binding to FcαRI on phagocytes. Thus, serum IgA and lamina propria dIgA can work as second line barrier against translocated bacteria from the gut lumen to lamina propria, portal blood, and the liver which is observed in patients with ALD and NAFLD/NASH. However, excessive activation of this function potentially can lead to local inflammation. There is no study investigating the role and expression of FcαRI in the liver and/or gut of patients with ALD and NAFLD/NASH and of animal models. These studies are necessary to understand the precise role of IgA on pathogenesis of diseases.

**Future directions**

The intestinal microbiome has been suggested to contribute to the development and progression of ALD and NAFLD/NASH. However, precise mechanisms how the gut microbiome contributes to the disease pathogenesis and how the development of diseases disrupts gut homeostasis are not fully understood. Some features of altered gut microbiome, such as increased phylum Proteobacteria and Entero bacteriaceae family of bacteria, are shared between IgA-deficient animals and patients with and animal models of ALD and NAFLD/NASH. In addition, chronic feeding of alcohol and an obesogenic diet causing NAFLD/NASH led to decreased intestinal production of IgA in rodents. These facts imply the potential role of SIgA on the liver diseases. However, there are limited studies that investigate SIgA change in patients and reveal direct influence of IgA-deficiency on development of ALD, NAFLD or NASH. These studies are necessary in the future.

In addition to SIgA in the gut homeostasis, the role of circulating IgA, which is increased in ALD and NASH with cirrhosis, also requires to be investigated in future studies. It has been suggested that FcαRI on Kupffer cells and neutrophils contribute to elimination of gut-derived bacteria and its products via activating phagocytosis. However, it has been difficult to investigate the role of IgA-FcαRI in development of the liver diseases because mice lack equivalent receptor of human FcαRI. To apply the transgenic mice introduced with the human FcαRI gene to investigate the role could be a solution of the problem.

**Acknowledgements** This work was supported in part by JSPS Grant-in-Aid for Young Scientists (B) 17K15953 (to TI) and NIH Grants R01 AA020703, U01 AA24726 and U01 AA021856 (to BS) and by Award I01BX002213 from the Biomedical Laboratory Research and Development Service of the VA Office of Research and Development (to BS).

**Compliance with ethical standards**

**Conflict of interest** There is no conflict of interest.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780–5.
2. Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139(1844–1854):e1.
3. Turnbaugh PJ, Hamady M, Yatsunenko T, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–4.
4. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–6.
5. Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490:55–60.
6. Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103.
7. Hsiao EY, McBride SW, Hsien S, et al. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013;155:1451–63.
8. Kang D-W, Park JG, Ilhan ZE, et al. Reduced incidence of infection immunity. Nat Rev Microbiol. 2010;8:656–67.
9. Strugnell RA, Wijburg OLC. The role of secretory antibodies in gut. Cell Physiol Physiol Gastrointest Liver Physiol. 2012;302:G168–75.
10. Tovar J, Willey F, Herbst F, et al. Immunoglobulin A (IgA) or IgM antibodies. Infect Immun. 1989;9:763–84.
11. Moro-Sibilot L, Blanc P, Taillardet M, et al. Mouse and human liver contain immunoglobulin A—secreting cells originating from Peyer’s patches and directed against intestinal antigens. Gastroenterology. 2016;151:311–23.
12. Chen Y, Yang F, Lu H, et al. Characterization of fecal microbiota in patients with liver cirrhosis. Hepatology. 2011;54:562–72.
13. Zhu L, Baker SS, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology. 2013;57:601–9.
14. Bajaj JS, Ridlon JM, Hylemon PB, et al. Linkage of gut microbiome with cognition in autistic children. PLoS One. 2013;8:e68322.
15. Suzuki K, Meek B, Doi Y, et al. Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci USA. 2004;101:1981–6.
16. Wei M, Shinkura R, Doi Y, et al. Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol. 2011;12:264–70.
17. Szabo G, Petrasek J. Gut-liver axis and sterile signals in the development of alcoholic liver disease. Alcohol Alcohol. 2017;52:414–24.
18. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513–24.
19. tilt H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016;65:2035–44.
20. Honda K, Littman DR. The microbiota in adaptive immune homeostasis and disease. Nature. 2016;535:75–84.
21. Fagarasan S, Kawamoto S, Kanagawa O, et al. Adaptive immune regulation in the gut: T cell-dependent and T cell-independent IgA synthesis. Annu Rev Immunol. 2010;28:243–73.
22. Lycke N, Erlandsson L, Ekman L, et al. Lack of J chain inhibits the transport of gut IgA and abrogates the development of intestinal antitoxic protection. J Immunol. 1999;163:913–9.
23. Harriman GR, Gogue M, Rogers P, et al. Targeted deletion of the IgA constant region in mice leads to IgA deficiency with...
alterations in expression of other Ig isotypes. J Immunol. 1999;162:2521–9.
43. Yel L. Selective IgA Deficiency. J Clin Immunol. 2010;30:10–6.
44. Friman V, Nowrouzian F, Adlerberth I, et al. Increased frequency of intestinal Escherichia coli carrying genes for S limbriae and haemolysin in IgA-deficient individuals. Microb Pathog. 2002;32:35–42.
45. Kirpich IA, Marsano LS, McClain CJ. The Canadian Society of Clinical Chemists. Gut–liver axis, nutrition, and non-alcoholic fatty liver disease. Clin Biochem. 2015;48:923–30.
46. Szabo G. Gut–liver axis in alcoholic liver disease. Gastroenterology. 2015;148:30–6.
47. Hartmann P, Seebauer CT, Schnabl B. Alcoholic liver disease: the gut microbiome and liver cross talk. Alcohol Clin Exp Res. 2015;39:763–75.
48. Leung C, Rivera L, Furness JB, et al. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016;13:412–25.
49. Hartmann P, Chen P, Wang HJ, et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice. Hepatology. 2013;58:108–19.
50. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microbiota improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374–83.
51. Hilebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137(1716–1724):e2.
52. Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol. 2015;1:275–84.
53. Hartmann P, Chen W-C, Schnabl B. The intestinal microbiome and the leaky gut as therapeutic targets in alcoholic liver disease. Front Physiol. 2012;3:402.
54. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology. 2009;50:638–44.
55. Schäfer C, Parlesak A, Schütt C, et al. Concentrations of lipopolysaccharide-binding protein, bacterial/endothelial increasing protein, soluble CD14 and plasma lipids in relation to endotoxaemia in patients with alcoholic liver disease. Alcohol Alcohol. 2002;37:81–6.
56. Bala S, Marcos M, Gattu A, et al. Acute binge drinking increases serum endotoxin and bacterial DNA levels in healthy individuals. PLoS One. 2014;9:e96861.
57. Fujimoto M, Umura M, Nakatani Y, et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res. 2000;24:485–545.
58. Bajaj JS, Heuman DM, Hylemon PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol. 2014;60:940–7.
59. Lippai D, Bala S, Catalano D, et al. Micro-RNA-155 deficiency prevents alcohol-induced serum endotoxin increase and small bowel inflammation in mice. Alcohol Clin Exp Res. 2014;38:2217–24.
60. Tabata T, Tani T, Endo Y, et al. Bacterial translocation and peptidoglycan translocation by acute ethanol administration. J Gastroenterol. 2002;37:726–31.
61. Verma VK, Li H, Wang R, et al. Alcohol stimulates macrophase activation through caspase-dependent hepatocyte derived release of CD40L containing extracellular vesicles. J Hepatol. 2016;64:651–60.
62. Iracheta-VELVYE A, Petrasek J, Satishchandran A, et al. Inhibition of sterile danger signals, uric acid and ATP, prevents inflammation and protects from alcoholic steatohepatitis in mice. J Hepatol. 2015;63:1147–55.
63. Yang A-M, Inamine T, Hochrath K, et al. Intestinal fungi contribute to development of alcoholic liver disease. J Clin Invest. 2017;127:2829–41.
64. Rivera CA, Adegbuyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 2007;47:571–9.
65. Cani PD, Amar J, Iglesias MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56:1761–72.
66. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008;57:1470–81.
67. Kodama Y, Kisseleva T, Iwaisako K, et al. c-Jun N-terminal kinase-1 from hematopoietic cells mediates progression from hepatic steatosis to steatohepatitis and fibrosis in mice. Gastroenterology. 2009;137(1467–1477):e5.
68. Alisi A, Manco M, Devito R, et al. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr. 2010;50:645–9.
69. Harte AL, de Silva NF, Creely SJ, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm. 2010;7:15.
70. Miura K. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:7381–91.
71. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004;101:15718–23.
72. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA [Internet]. 2007;104:9979–84. Available from: http://www.pnas.org/lookup/doi/10.1073/pnas.0605374104.
73. Turnbaugh PJ, Ley RE, Mahowald MA, et al. An obesity-associated gut microbiota with increased capacity for energy harvest. Nature. 2006;444:1027–131.
74. Dumas M-E, Barton RH, Toyé A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA. 2006;103:12511–6.
75. Naz S, Cope K, Terence RH, et al. Obesity and female gender increase breath ethanol concentration: potential implications for the pathogenesis of non-alcoholic steatohepatitis. Am J Gastroenterol. 2001;96:1200–4.
76. Lee FL. Immunoglobulins in viral hepatitis and active alcoholic liver disease. Lancet. 1965;2:1043–6.
77. Inamine T, Yang A-M, Wang L, et al. Genetic loss of immunoglobulin A does not influence development of alcoholic steatohepatitis in mice. Alcohol Clin Exp Res. 2016;40:2604–13.
78. Goldin RD, Cattle S, Boylston AW. IgA deposition in alcoholic liver disease. J Clin Pathol. 1986;39:1181–5.
79. Van De Wiel A, Delacroix DL, Van Hattum J, et al. Characteristics of serum IgA and liver IgA deposits in alcoholic liver disease. Hepatology. 1987;7:95–9.
80. Walsh K. Alcoholic liver disease. Postgrad Med J. 2000;76:280–6.
81. Souza HS, Elia CC, Braulio VB, et al. Effects of ethanol on gut-associated lymphoid tissues in a model of bacterial translocation: a possible role of apotosis. Alcohol. 2003;30:183–91.
82. López MC. Chronic alcohol consumption regulates the expression of poly immunoglobulin receptor (pIgR) and secretory IgA in the gut. Toxicol Appl Pharmacol. 2017;333:84–91.
83. Budeč M, Markovic D, Vignjivic S, et al. Neuronal nitric oxide synthase mediates the effect of ethanol on IgA. Alcohol Alcohol. 2013;48:53–8.
84. Budeč M, Koko V, Todorović V, et al. Possible mechanism of acute effect of ethanol on intestinal IgA expression in rat. Int Immunopharmacol. 2007;7:858–63.
85. Budeč M, Todorović V, Dmdarević N. Acute effect of ethanol on IgA immunoreactive cells in the intestine-associated immune system. Pharmacol Rep. 2005;57:385–9.
86. Pelletier G, Briandais MJ, Buffet C, et al. Serum and intestinal secretory IgA in alcoholic cirrhosis of the liver. Gut. 1982;23:475–80.
87. Colombel JF, Vaerman JP, Mesnard B, et al. Jejunal immunoglobulin secretion in alcoholic patients with and without cirrhosis. J Hepatol. 1991;12:145–9.
88. Maier A, Bode C, Fritz P, et al. Effects of chronic alcohol abuse on duodenal mononuclear cells in man. Dig Dis Sci. 1999;44:691–6.
89. Tomita K, Teratani T, Yokoyama H, et al. Serum immunoglobulin A concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage. Dig Dis Sci. 2011;56:3648–54.
90. McPherson S, Henderson E, Burt AD, et al. Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol. 2014;60:1055–62.
91. Maleki I, Aminafshar MR, Taghvaei T, et al. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:12566–73.
92. Okazaki Y, Han Y, Kayahara M, et al. Consumption of curcumin elevates fecal immunoglobulin A, an index of intestinal immune function, in rats fed a high-fat diet. J Nutr Sci Vitaminol. 2010;56:68–71.
93. Okazaki Y, Tomotake H, Tsujimoto K, et al. Consumption of a resistant protein, sericin, elevates fecal immunoglobulin A, mucins, and cecal organic acids in rats fed a high-fat diet. J Nutr. 2011;141:1975–81.
94. Matsumoto K, Ichimura M, Tsuneyama K, et al. Fructooligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis. PLoS One. 2017;12:e0175406.
95. Li S, Wu W-C, He C-Y, et al. Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats. World J Gastroenterol. 2008;14:3254–8.
96. Taïra T, Yamaguchi S, Takahashi A, et al. Dietary polyphenols increase fecal mucin and immunoglobulin A and ameliorate the disturbance in gut microbiota caused by a high fat diet. J Clin Biochem Nutr. 2015;57:212–6.
97. Shin N-R, Whon TW, Bae J-W. Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol. 2015;33:496–503.
98. Moon C, Baldridge MT, Wallace MA, et al. Vertically transmitted faecal IgA levels determine extra-chromosomal phenotype variation. Nature. 2015;521:90–3.
99. Michail S, Lin M, Frey MR, et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol Ecol. 2015;91:1–9.
100. Jiang W, Wu N, Wang X, et al. Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. Sci Rep. 2015;5:8096.
101. Tian Y, Wang H, Yuan F, et al. Perilla oil has similar protective effects of fish oil on high-fat diet-induced nonalcoholic fatty liver disease and gut dysbiosis. Biomed Res Int. 2016;2016:9462571.
102. Raso GM, Simeoli R, Iacono A, et al. Effects of a Lactobacillus paracasei B21060 based symbiotic on steatosis, insulin signaling and Toll-like receptor expression in rats fed a high-fat diet. J Nutr Biochem. 2014;25:81–90.
103. Rahman K, Desai C, Iyer SS, et al. Loss of junctional adhesion molecule a promotes severe steatohepatitis in mice on a diet high in saturated fat, fructose, and cholesterol. Gastroenterology. 2016;151(733–746):e12.
104. Yin X, Peng J, Zhao L, et al. Structural changes of gut microbiota in a rat non-alcoholic fatty liver disease model treated with a Chinese herbal formula. Syst Appl Microbiol. 2013;36:188–96.
105. Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016;63:764–75.
106. Mouzaki M, Cornelli EM, Arendt BM, et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120–7.
107. Yan AW, Fouts DE, Brandl J, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011;53:96–105.
108. Bull-Ottersen L, Feng W, Kirpich I, et al. Metagenomic analyses of alcohol-induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One. 2013;8:e53028.
109. Wang L, Fouts DE, Stärkel P, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation. Cell Host Microbe. 2016;19:227–39.
110. Kirpich IA, Solovieva NV, Leikhter SN, et al. Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol. 2008;42:675–82.
111. Bluemel S, Williams B, Knight R, et al. Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. Am J Physiol Gastrointest Liver Physiol. 2016;311:G1018–36.
112. Mutlu EA, Gilleveit PM, Rangwala H, et al. Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol. 2012;302:G966–78.
113. Llopis M, Cassard AM, Wrzosek L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease. Gut. 2016;65:830–9.
114. Kakiyama G, Pandak WM, Gilleveit PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol. 2013;58:949–55.
115. Heineke MH, van Egmond M. Immunoglobulin A: magic bullet or Trojan horse? Eur J Clin Invest. 2017;47:184–92.
116. Aleyd E, Heineke MH, van Egmond M. The era of the immunoglobulin A Fc receptor FcαRI; its function and potential as target in disease. Immunol Rev. 2015;268:123–38.
117. van Egmond M, van Garderen E, van Spriel AB, et al. FcαRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med. 2000;6:680–5.
118. Reljic R. In search of the elusive mouse macrophage Fc-alpha receptor. Immunol Lett. 2006;107:80–1.
119. van der Steen L, Tuk CW, Bakema JE, et al. Immunoglobulin A: FcαRI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology. 2009;137:2029–3.